series-c-plus
Stage
About
Albireo Pharma, Inc. is a biopharmaceutical company developing therapies for rare pediatric and adult cholestatic liver diseases; its lead product, odevixibat (Bylvay), is an oral ileal bile acid transporter inhibitor approved for certain rare cholestatic liver conditions.
Explore Albireo Pharma, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.